Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...
Tensions in the Strait of Hormuz are raising alarms about the stability of global pharmaceutical supply chains, with potential implications for the U.S. generic drug market, which relies heavily on ...
A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...
Novartis AG forecast a profit decline for this year as some of the Swiss drugmaker’s top sellers like the heart medicine Entresto get further hit by generic competition. Core operating income will ...
Canadians face a longer-than-expected wait for cheaper versions of Novo Nordisk A/S’s diabetes drug Ozempic after two of the biggest generics makers were hit with additional requests from the health ...
Cuban urges FDA fee waiver to boost US generics manufacturing Cost Plus Drugs plans to boost US production if fees are waived FDA charges $360,000 per generic drug approval application Trump promised ...
🚀 A comprehensive Java fundamentals guide designed to prepare backend developers for Spring Framework mastery. 12 focused modules covering OOP, collections, concurrency, design patterns, and more - ...
CEO Narasimhan says no tariff impact on guidance Top-selling heart drug Entresto sees growth stall Older drugs hit by 'generic erosion' in US market Newer drugs help offset some of the slowdown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results